These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12737113)

  • 1. Can OI prophylaxis be stopped in patients responding to HAART?
    Boyle BA
    AIDS Read; 1999 Jul; 9(4):240-2, 245. PubMed ID: 12737113
    [No Abstract]   [Full Text] [Related]  

  • 2. Recommendations for fungal opportunistic infections prevention in persons infected with human immunodeficiency virus.
    Popa LG; Popa MI; Zaharia A; Ocneanu M
    Roum Arch Microbiol Immunol; 1999; 58(2):185-95. PubMed ID: 11845456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting CD4 count using total lymphocyte count: a sustainable tool for clinical decisions during HAART use.
    Mwamburi DM; Ghosh M; Fauntleroy J; Gorbach SL; Wanke CA
    Am J Trop Med Hyg; 2005 Jul; 73(1):58-62. PubMed ID: 16014833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti retroviral therapy (ART) on CD4 T lymphocyte count and the spectrum of opportunistic infections in HIV/AIDS in Manipur.
    Chitra Y; Urgen S; Dayananda I; Brajachand SN
    J Commun Dis; 2009 Mar; 41(1):19-24. PubMed ID: 19886171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of highly active antiretroviral therapy for childhood acquired immunodeficiency syndrome].
    Hao JL; Wang BJ; Baptiste J
    Zhongguo Dang Dai Er Ke Za Zhi; 2010 Nov; 12(11):874-6. PubMed ID: 21083982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotrimoxazole prophylaxis in HIV-infected pregnant women: only a first step.
    Heather Watts D; Mofenson LM
    J Infect Dis; 2006 Dec; 194(11):1478-80. PubMed ID: 17083031
    [No Abstract]   [Full Text] [Related]  

  • 9. Salvaging HAART.
    Laurence J
    AIDS Read; 1999 Jul; 9(4):234-5. PubMed ID: 12737111
    [No Abstract]   [Full Text] [Related]  

  • 10. Guidelines for diagnosis and treatment of HIV/AIDS in China (2005).
    ;
    Chin Med J (Engl); 2006 Oct; 119(19):1589-608. PubMed ID: 17042972
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients.
    Lilleri D; Piccinini G; Genini E; Comolli G; Chiesa A; Tordato F; Sotgiu G; Parisi A; Baldanti F; Revello MG; Gerna G
    J Clin Virol; 2004 Apr; 29(4):297-307. PubMed ID: 15018859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant responses to HAART in HIV-1 patients: the need to focus on intervention.
    De Maria A
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):523-7. PubMed ID: 17678414
    [No Abstract]   [Full Text] [Related]  

  • 13. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [No standard: drug holidays in HAART. Continuous or interval treatment?].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():81. PubMed ID: 15011601
    [No Abstract]   [Full Text] [Related]  

  • 16. [Severe opportunistic infections in HIV-positive adults in sub-Saharan Africa].
    Anglaret X
    Med Trop (Mars); 2006 Aug; 66(4):343-5. PubMed ID: 16999042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-trimoxazole prophylaxis in tropical countries in the era of highly active antiretroviral therapy: do we know enough?
    Lynen L; Jacobs J; Colebunders R
    Trans R Soc Trop Med Hyg; 2007 Nov; 101(11):1059-60. PubMed ID: 17662321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.
    McCutchan JA; Wu JW; Robertson K; Koletar SL; Ellis RJ; Cohn S; Taylor M; Woods S; Heaton R; Currier J; Williams PL
    AIDS; 2007 May; 21(9):1109-17. PubMed ID: 17502721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression to AIDS and death in the era of HAART.
    Hill A
    AIDS; 2006 Apr; 20(7):1067-8. PubMed ID: 16603862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.